Dr. Reddy’s Laboratories reported a 22% increase in net profit for the fourth quarter, reaching ₹1,594 crore compared to the same period last year. Revenue from operations also grew by 20% year-on-year, totaling ₹8,506 crore, up from ₹7,083 crore in Q4 of the previous year. Compared to the third quarter, revenue saw a slight 2% increase from ₹8,358.6 crore.
Read More: Titan’s Shares Rise 3.2% as Quarterly Profit Grows 13% YoY to ₹871 Crore
The company’s net profit also grew by 13% when compared to the previous quarter, where it stood at ₹1,413.3 crore. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the quarter was ₹2,474.9 crore, making up 29% of its total revenue.
For shareholders, the company recommended a final dividend of ₹8 per share for the financial year 2024-25.
Dr. Reddy’s global generics business saw strong performance, with North America contributing ₹3,559 crore in revenue, a 9% rise from last year. Revenue from Europe grew significantly by 145% to ₹1,275 crore, which includes ₹597 crore from the recently acquired NRT business. In India, revenue increased by 16% to ₹1,305 crore.
The Pharmaceutical Services & Active Ingredients (PSAI) segment also showed growth, with revenue rising by 16% to ₹956.3 crore.
For the full year, Dr. Reddy’s net profit increased slightly by 1.38%, totaling ₹5,655.1 crore, and net sales rose 16.61% to ₹32,553.5 crore.
Also Read: Q4 Performance: Coal India Posts 12% Jump in Q4 Earnings and Shares Rises 1.7%
Dr. Reddy’s co-chairman and MD, G V Prasad, stated that the company achieved strong growth due to successful product launches, higher sales from key U.S. products, and the integration of the NRT business. Looking ahead, the company plans to continue growing by managing its product portfolio well, improving operations, and seeking new partnerships and acquisitions.
Also See: Britannia Industries Q4 Results: Profit Jumps 4% to ₹560 Crore with ₹75 Dividend
Dr. Reddy’s Laboratories, based in Hyderabad, is a leading global pharmaceutical company offering a wide range of products, including generic medicines, biosimilars, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) drugs.
